Molecular Targeted Agents for Stage III NSCLC

November 15, 2013
Bilal Piperdi, MD

Special Reports, NSCLC (Issue 1), Volume 1, Issue 1

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, comments on molecular targeted agents for stage III non-small cell lung cancer (NSCLC).

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, comments on molecular targeted agents for stage III non-small cell lung cancer (NSCLC).

Read more aboutmolecular targets in NSCLC